IGFBP7 overexpression IGFBP7 overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	IGFBP7 overexpression IGFBP7 overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: B - Late Trials Carcinogenesis - 1 week	tamoxifen Sensitive: B - Late Trials Carcinogenesis - 1 week
ASXL1 mutation ASXL1 mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ASXL1 mutation ASXL1 mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CDK6 inhibitor Sensitive: C3 – Early Trials SABCS 2021 - 1 week	CDK6 inhibitor Sensitive: C3 – Early Trials SABCS 2021 - 1 week
ASXL1 mutation ASXL1 mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ASXL1 mutation ASXL1 mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CDK4 inhibitor Sensitive: C3 – Early Trials SABCS 2021 - 1 week	CDK4 inhibitor Sensitive: C3 – Early Trials SABCS 2021 - 1 week
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval	Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval	Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval	Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval	Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval	Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval	Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval	Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval	Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval	Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval	Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ribociclib Sensitive: A1 - Approval	ribociclib Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lapatinib Sensitive: A1 - Approval	lapatinib Sensitive: A1 - Approval
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval	fulvestrant Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval	neratinib Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	olaparib Sensitive: A1 - Approval	olaparib Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval	neratinib Sensitive: A1 - Approval
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	exemestane Sensitive: A1 - Approval	exemestane Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	letrozole Sensitive: A1 - Approval	letrozole Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	anastrozole Sensitive: A1 - Approval	anastrozole Sensitive: A1 - Approval
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	toremifene Sensitive: A1 - Approval	toremifene Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: A1 - Approval	talazoparib Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval	fulvestrant Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	palbociclib Resistant: A2 - Guideline	palbociclib Resistant: A2 - Guideline
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	everolimus Sensitive: A2 - Guideline	everolimus Sensitive: A2 - Guideline
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Aromatase inhibitor + palbociclib Sensitive: A2 - Guideline	Aromatase inhibitor + palbociclib Sensitive: A2 - Guideline
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline	Aromatase inhibitor Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	BRCA2 mutation BRCA2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline	PARP inhibitor Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline	PARP inhibitor Sensitive: A2 - Guideline
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	CDK6 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline	CDK6 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	CDK4 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline	CDK4 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	trastuzumab + lapatinib Resistant: B - Late Trials	trastuzumab + lapatinib Resistant: B - Late Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	trastuzumab Resistant: B - Late Trials	trastuzumab Resistant: B - Late Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lapatinib Resistant: B - Late Trials	lapatinib Resistant: B - Late Trials
CCNE1 overexpression CCNE1 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	CCNE1 overexpression CCNE1 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	palbociclib Resistant: B - Late Trials	palbociclib Resistant: B - Late Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials	palbociclib Sensitive: B - Late Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	tamoxifen Sensitive: B - Late Trials	tamoxifen Sensitive: B - Late Trials
PLK1-H PLK1-H	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PLK1-H PLK1-H	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	palbociclib Resistant: B - Late Trials	palbociclib Resistant: B - Late Trials
TP53 mutation TP53 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	TP53 mutation TP53 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	capecitabine Resistant: B - Late Trials	capecitabine Resistant: B - Late Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	capecitabine Sensitive: B - Late Trials	capecitabine Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ABT-888 Sensitive: B - Late Trials	ABT-888 Sensitive: B - Late Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	palbociclib + abemaciclib Sensitive: B - Late Trials	palbociclib + abemaciclib Sensitive: B - Late Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	alpelisib Sensitive: B - Late Trials	alpelisib Sensitive: B - Late Trials
BRCA2 mutation BRCA2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	BRCA2 mutation BRCA2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ABT-888 Sensitive: B - Late Trials	ABT-888 Sensitive: B - Late Trials
ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials	exemestane Resistant: B - Late Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials	fulvestrant Sensitive: B - Late Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials	exemestane Resistant: B - Late Trials
FGFR1 amplification FGFR1 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	FGFR1 amplification FGFR1 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	letrozole Resistant: B - Late Trials	letrozole Resistant: B - Late Trials
ER rs2234693 ER rs2234693	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ER rs2234693 ER rs2234693	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	exemestane Sensitive: B - Late Trials	exemestane Sensitive: B - Late Trials
HSD17B2 overexpression HSD17B2 overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	HSD17B2 overexpression HSD17B2 overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: B - Late Trials	tamoxifen Sensitive: B - Late Trials
ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials	fulvestrant Sensitive: B - Late Trials
HR positive + HER-2 positive HR positive + HER-2 positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive + HER-2 positive HR positive + HER-2 positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Aromatase inhibitor + trastuzumab + lapatinib Sensitive: B - Late Trials	Aromatase inhibitor + trastuzumab + lapatinib Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: B - Late Trials	talazoparib Sensitive: B - Late Trials
BRCA2 mutation BRCA2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	BRCA2 mutation BRCA2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: B - Late Trials	talazoparib Sensitive: B - Late Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	abemaciclib Resistant: C1 - Off-label	abemaciclib Resistant: C1 - Off-label
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	alpelisib Sensitive: C1 - Off-label	alpelisib Sensitive: C1 - Off-label
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria	Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	SAR439859 Sensitive: C2 – Inclusion Criteria	SAR439859 Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HER-2 mutation HER-2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	enzalutamide Sensitive: C2 – Inclusion Criteria	enzalutamide Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	alpelisib Sensitive: C2 – Inclusion Criteria	alpelisib Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: C2 – Inclusion Criteria	palbociclib Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	alpelisib + fulvestrant Sensitive: C2 – Inclusion Criteria	alpelisib + fulvestrant Sensitive: C2 – Inclusion Criteria
EPRS1 expression EPRS1 expression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	EPRS1 expression EPRS1 expression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials	tamoxifen Sensitive: C3 – Early Trials
FTO expression FTO expression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	FTO expression FTO expression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials	tamoxifen Sensitive: C3 – Early Trials
CTDSP1 expression CTDSP1 expression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CTDSP1 expression CTDSP1 expression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials	tamoxifen Sensitive: C3 – Early Trials
BIN3 expression BIN3 expression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	BIN3 expression BIN3 expression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials	tamoxifen Sensitive: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	bevacizumab Sensitive: C3 – Early Trials	bevacizumab Sensitive: C3 – Early Trials
ER Y537S ER Y537S	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER Y537S ER Y537S	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: C3 – Early Trials	fulvestrant Sensitive: C3 – Early Trials
PIK3R1 mutation PIK3R1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PIK3R1 mutation PIK3R1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Resistant: C3 – Early Trials	lenvatinib Resistant: C3 – Early Trials
CDK6 overexpression CDK6 overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CDK6 overexpression CDK6 overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Resistant: C3 – Early Trials	fulvestrant Resistant: C3 – Early Trials
RSF1 amplification RSF1 amplification	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	RSF1 amplification RSF1 amplification	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Resistant: C3 – Early Trials	tamoxifen Resistant: C3 – Early Trials
USH2A mutation USH2A mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	USH2A mutation USH2A mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Sensitive: C3 – Early Trials	lenvatinib Sensitive: C3 – Early Trials
NEFH mutation NEFH mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	NEFH mutation NEFH mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Sensitive: C3 – Early Trials	lenvatinib Sensitive: C3 – Early Trials
APC mutation APC mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	APC mutation APC mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Resistant: C3 – Early Trials	lenvatinib Resistant: C3 – Early Trials
PTCH1 mutation PTCH1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PTCH1 mutation PTCH1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Sensitive: C3 – Early Trials	lenvatinib Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PALB2 mutation PALB2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Resistant: C3 – Early Trials	lenvatinib Resistant: C3 – Early Trials
NOS2 underexpression NOS2 underexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	NOS2 underexpression NOS2 underexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials	tamoxifen Sensitive: C3 – Early Trials
TK1-H TK1-H	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	TK1-H TK1-H	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Sensitive: C3 – Early Trials	fulvestrant + anastrozole Sensitive: C3 – Early Trials
HPGD underexpression HPGD underexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	HPGD underexpression HPGD underexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Resistant: C3 – Early Trials	tamoxifen Resistant: C3 – Early Trials
BRCA2 mutation BRCA2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	BRCA2 mutation BRCA2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Resistant: C3 – Early Trials	fulvestrant + anastrozole Resistant: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Resistant: C3 – Early Trials	fulvestrant + anastrozole Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Sensitive: C3 – Early Trials	fulvestrant + anastrozole Sensitive: C3 – Early Trials
CCNE1 overexpression CCNE1 overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CCNE1 overexpression CCNE1 overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials	palbociclib Resistant: C3 – Early Trials
CDK2 overexpression CDK2 overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CDK2 overexpression CDK2 overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials	palbociclib Resistant: C3 – Early Trials
CCND1 amplification CCND1 amplification	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CCND1 amplification CCND1 amplification	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials	palbociclib Resistant: C3 – Early Trials
CCNE1-H CCNE1-H	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CCNE1-H CCNE1-H	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials	palbociclib Resistant: C3 – Early Trials
ER-L ER-L	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER-L ER-L	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials	palbociclib Resistant: C3 – Early Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	enobosarm Sensitive: C3 – Early Trials	enobosarm Sensitive: C3 – Early Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	pazopanib Sensitive: C3 – Early Trials	pazopanib Sensitive: C3 – Early Trials
RB1 deletion RB1 deletion	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	RB1 deletion RB1 deletion	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials	palbociclib Resistant: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen + TAK-228 Sensitive: C3 – Early Trials	tamoxifen + TAK-228 Sensitive: C3 – Early Trials

Hormone Receptor Positive Breast Cancer

Associations(210)

Associations
(210)